0001144204-17-065970.txt : 20171229 0001144204-17-065970.hdr.sgml : 20171229 20171229181613 ACCESSION NUMBER: 0001144204-17-065970 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20171219 FILED AS OF DATE: 20171229 DATE AS OF CHANGE: 20171229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pontifax (Cayman) IV L.P. CENTRAL INDEX KEY: 0001726029 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31326 FILM NUMBER: 171282850 BUSINESS ADDRESS: STREET 1: 4 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 BUSINESS PHONE: 972-9-9725617 MAIL ADDRESS: STREET 1: 4 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pontifax (China) IV L.P. CENTRAL INDEX KEY: 0001726030 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31326 FILM NUMBER: 171282848 BUSINESS ADDRESS: STREET 1: 14 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 BUSINESS PHONE: 972-9-9725617 MAIL ADDRESS: STREET 1: 14 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pontifax (Israel) IV, L.P. CENTRAL INDEX KEY: 0001726039 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31326 FILM NUMBER: 171282849 BUSINESS ADDRESS: STREET 1: 14 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 BUSINESS PHONE: 972-9-9725617 MAIL ADDRESS: STREET 1: 14 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pontifax IV GP L.P. CENTRAL INDEX KEY: 0001726353 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31326 FILM NUMBER: 171282851 BUSINESS ADDRESS: STREET 1: 14 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 BUSINESS PHONE: 972-9-9725617 MAIL ADDRESS: STREET 1: 14 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pontifax Management 4 G.P. (2015) Ltd. CENTRAL INDEX KEY: 0001726334 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31326 FILM NUMBER: 171282852 BUSINESS ADDRESS: STREET 1: 14 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 BUSINESS PHONE: 972-9-9725617 MAIL ADDRESS: STREET 1: 14 SHENKAR STREET, BEIT OFEK CITY: HERZLIYA PITUACH STATE: L3 ZIP: 46140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eloxx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001035354 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 841368850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (858) 909-0749 MAIL ADDRESS: STREET 1: 950 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Sevion Therapeutics, Inc. DATE OF NAME CHANGE: 20140930 FORMER COMPANY: FORMER CONFORMED NAME: SENESCO TECHNOLOGIES INC DATE OF NAME CHANGE: 19991006 FORMER COMPANY: FORMER CONFORMED NAME: NAVA LEISURE USA INC DATE OF NAME CHANGE: 19970310 3 1 tv482318_3.xml FORM 3 X0206 3 2017-12-19 0 0001035354 Eloxx Pharmaceuticals, Inc. SVOND 0001726334 Pontifax Management 4 G.P. (2015) Ltd. C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET, 4TH FLOOR NORTH WALTHAM MA 02451 0 0 1 0 0001726353 Pontifax IV GP L.P. C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET, 4TH FLOOR NORTH WALTHAM MA 02451 0 0 1 0 0001726029 Pontifax (Cayman) IV L.P. C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET, 4TH FLOOR NORTH WALTHAM MA 02451 0 0 1 0 0001726039 Pontifax (Israel) IV, L.P. C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET, 4TH FLOOR NORTH WALTHAM MA 02451 0 0 1 0 0001726030 Pontifax (China) IV L.P. C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET, 4TH FLOOR NORTH WALTHAM MA 02451 0 0 1 0 Common Stock 381518 I By Pontifax Investment Fund Common Stock 783664 I By Pontifax Investment Fund Common Stock 423703 I By Pontifax Investment Fund Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Exhibit 24.1 - Pontifax Management 4 G.P. (2015) Ltd. Power of Attorney. Exhibit 24.2 - Pontifax IV GP L.P. Power of Attorney. Exhibit 24.3 - Pontifax (Cayman) IV L.P. Power of Attorney. Exhibit 24.4 - Pontifax (Israel) IV, L.P. Power of Attorney Exhibit. 24.5 - Pontifax (China) IV L.P. Power of Attorney. Pontifax Management 4 G.P. (2015) Ltd. /s/ Gregory Weaver, Attorney in Fact on behalf of Tomer Kariv, Chief Executive Officer 2017-12-29 Pontifax IV GP L.P. /s/ Gregory Weaver, Attorney in Fact on behalf of Tomer Kariv, Chief Executive Officer 2017-12-29 Pontifax (Cayman) IV L.P. /s/ Gregory Weaver, Attorney in Fact on behalf of Tomer Kariv, Chief Executive Officer 2017-12-29 Pontifax (Israel) IV, L.P. /s/ Gregory Weaver, Attorney in Fact on behalf of Tomer Kariv, Chief Executive Officer 2017-12-29 Pontifax (China) IV L.P. /s/ Gregory Weaver, Attorney in Fact on behalf of Tomer Kariv, Chief Executive Officer 2017-12-29 EX-24.1 2 tv482318_ex24-1.htm EXHIBIT 24.1

 

Exhibit 24.1

 

LIMITED POWER OF ATTORNEY

 

The undersigned hereby constitutes and appoints Gregory Weaver with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

 

(1)prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

 

(2)execute for and on behalf of the undersigned, in the undersigned’s capacity as officer and/or director of Eloxx Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

 

(3)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

 

(4)take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.


[Remainder of page intentionally left blank]

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of December, 2017.

 

  Pontifax Management 4 G.P. (2015) Ltd.
     
     
     
  By: /s/ Tomer Kariv
  Name: Tomer Kariv
  Title: Chief Executive Officer

 

 

 

 

 EX-24.2 3 tv482318_ex24-2.htm EXHIBIT 24.2

 

Exhibit 24.2

 

LIMITED POWER OF ATTORNEY

 

The undersigned hereby constitutes and appoints Gregory Weaver with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

 

(1)prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

 

(2)execute for and on behalf of the undersigned, in the undersigned’s capacity as officer and/or director of Eloxx Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

 

(3)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

 

(4)take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.


[Remainder of page intentionally left blank]

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of December, 2017.

 

  Pontifax IV GP L.P.
     
     
     
  By: /s/ Tomer Kariv
  Name: Tomer Kariv
  Title: Chief Executive Officer

 

 

 EX-24.3 4 tv482318_ex24-3.htm EXHIBIT 24.3

 

Exhibit 24.3

 

LIMITED POWER OF ATTORNEY

 

The undersigned hereby constitutes and appoints Gregory Weaver with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

 

(1)prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

 

(2)execute for and on behalf of the undersigned, in the undersigned’s capacity as officer and/or director of Eloxx Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

 

(3)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

 

(4)take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.


[Remainder of page intentionally left blank]

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of December, 2017.

 

 

  Pontifax (Cayman) IV L.P.
     
     
     
  By: /s/ Tomer Kariv
  Name: Tomer Kariv
  Title: Chief Executive Officer

 

 

 

 

 

 EX-24.4 5 tv482318_ex24-4.htm EXHIBIT 24.4

 

Exhibit 24.4

 

LIMITED POWER OF ATTORNEY

 

The undersigned hereby constitutes and appoints Gregory Weaver with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

 

(1)prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

 

(2)execute for and on behalf of the undersigned, in the undersigned’s capacity as officer and/or director of Eloxx Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

 

(3)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

 

(4)take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.


[Remainder of page intentionally left blank]

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of December, 2017.

 

  Pontifax (Israel) IV, L.P.
     
     
     
  By: /s/ Tomer Kariv
  Name: Tomer Kariv
  Title: Chief Executive Officer

 

 

 

 

 

 EX-24.5 6 tv482318_ex24-5.htm EXHIBIT 24.5

 

Exhibit 24.5

 

LIMITED POWER OF ATTORNEY

 

The undersigned hereby constitutes and appoints Gregory Weaver with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

 

(1)prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

 

(2)execute for and on behalf of the undersigned, in the undersigned’s capacity as officer and/or director of Eloxx Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

 

(3)do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

 

(4)take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.


[Remainder of page intentionally left blank]

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of December, 2017.

 

 

  Pontifax (China) IV L.P.
     
     
     
  By: /s/ Tomer Kariv
  Name: Tomer Kariv
  Title: Chief Executive Officer